REG - Allergy Therapeutics - Appointment of Chief Financial Officer

Allergy TherapeuticsAnnouncement

10/07/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230710:nRSJ5339Fa&default-theme=true

RNS Number : 5339F  Allergy Therapeutics PLC  10 July 2023

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Appointment of Chief Financial Officer

 

10 July 2023 Allergy Therapeutics plc (AIM: AGY), the integrated commercial
biotechnology company specialising in allergy vaccines, is pleased to announce
the promotion of Shaun Furlong to Chief Financial Officer (CFO) with effect
from 11 August, when the current interim CFO, Martin Hopcroft, will leave the
Company.

 

Shaun brings significant financial experience in both technical and commercial
roles. He joined Allergy Therapeutics as Group Financial Controller and a
member of the Group's senior management team in April 2022. He previously held
senior finance roles within blue-chip companies across multiple sectors,
including Legal & General, Hastings Direct, Volution Group and American
Express. He is a Fellow of the Institute of Chartered Accountants in England
and Wales, and holds a PhD in polymer chemistry from the University of Sussex.

 

Manuel Llobet, Chief Executive Officer, said: "I have had the pleasure of
working with Shaun for some time in his role as Group Financial Controller for
the Company and know him to be highly diligent and professional with strong
business acumen, so am delighted to welcome him in his new role. I also want
to take this opportunity to thank Martin Hopcroft for his expertise and
commitment during his time as interim CFO over recent months and wish him the
best for the future."

 

Shaun Furlong, incoming Chief Financial Officer, said: "I am excited to step
into my new role as CFO of Allergy Therapeutics, a pioneering company shaping
the future of innovative immunotherapies. Leveraging my industry experience, I
look forward to working with the leadership team."

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUUGMUPWGPU